Winslow Evans & Crocker Inc. maintained its position in Humana Inc. (NYSE:HUM) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,030 shares of the insurance provider’s stock at the end of the second quarter. Winslow Evans & Crocker Inc.’s holdings in Humana were worth $248,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Eqis Capital Management Inc. boosted its position in Humana by 2.7% in the second quarter. Eqis Capital Management Inc. now owns 9,452 shares of the insurance provider’s stock worth $2,274,000 after buying an additional 247 shares in the last quarter. Mn Services Vermogensbeheer B.V. boosted its position in Humana by 509.6% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 24,236 shares of the insurance provider’s stock worth $5,832,000 after buying an additional 20,260 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Humana during the second quarter worth approximately $5,434,000. National Pension Service boosted its position in Humana by 14.5% in the second quarter. National Pension Service now owns 131,943 shares of the insurance provider’s stock worth $31,579,000 after buying an additional 16,750 shares in the last quarter. Finally, State of Alaska Department of Revenue boosted its position in Humana by 467.2% in the second quarter. State of Alaska Department of Revenue now owns 9,422 shares of the insurance provider’s stock worth $2,266,000 after buying an additional 7,761 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Humana Inc. (NYSE HUM) opened at 239.07 on Monday. Humana Inc. has a 12 month low of $150.00 and a 12 month high of $243.74. The firm’s 50-day moving average is $232.54 and its 200-day moving average is $215.15. The stock has a market capitalization of $34.50 billion, a P/E ratio of 24.37 and a beta of 0.91.

Humana (NYSE:HUM) last released its earnings results on Wednesday, May 3rd. The insurance provider reported $2.75 earnings per share for the quarter, topping the consensus estimate of $2.55 by $0.20. Humana had a return on equity of 14.38% and a net margin of 2.71%. The business had revenue of $13.76 billion during the quarter, compared to the consensus estimate of $13.61 billion. During the same period last year, the company earned $1.86 earnings per share. On average, equities analysts expect that Humana Inc. will post $11.15 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 31st. Stockholders of record on Friday, June 30th will be given a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, June 28th. This represents a $1.60 annualized dividend and a dividend yield of 0.67%. Humana’s dividend payout ratio (DPR) is 16.24%.

TRADEMARK VIOLATION NOTICE: “Humana Inc. (HUM) Position Held by Winslow Evans & Crocker Inc.” was originally reported by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/humana-inc-hum-position-held-by-winslow-evans-crocker-inc/1444955.html.

A number of equities analysts have commented on the stock. Piper Jaffray Companies reissued a “buy” rating and issued a $246.00 price target on shares of Humana in a research note on Friday. Cowen and Company reissued a “buy” rating and issued a $230.00 price target on shares of Humana in a research note on Friday. Bank of America Corporation boosted their price target on shares of Humana from $270.00 to $275.00 and gave the stock a “buy” rating in a research note on Friday. Credit Suisse Group reissued an “outperform” rating and issued a $250.00 price target (up previously from $245.00) on shares of Humana in a research note on Thursday. Finally, UBS AG reissued a “neutral” rating and issued a $237.00 price target (up previously from $205.00) on shares of Humana in a research note on Wednesday, June 28th. Nine equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $231.00.

In other news, VP Heidi S. Margulis sold 1,500 shares of Humana stock in a transaction on Friday, May 26th. The stock was sold at an average price of $231.96, for a total transaction of $347,940.00. Following the completion of the sale, the vice president now directly owns 8,150 shares in the company, valued at $1,890,474. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Brian P. Leclaire sold 4,971 shares of Humana stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total value of $1,193,040.00. Following the sale, the senior vice president now owns 14,258 shares of the company’s stock, valued at $3,421,920. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 143,241 shares of company stock valued at $32,446,903. Corporate insiders own 0.80% of the company’s stock.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.